OverviewSuggest Edit

Repligen Corporation is a company that specializes in the development, production, and commercialization of products used for biological drug manufacturing. It offers hollow fiber filters, flat sheet cassettes, ligands and resins, TFDF (tangential flow depth filtration) systems, etc. The company focuses on a range of applications, including protein therapeutics, gene therapy, macromolecules, vaccines, and antibody-drug conjugates.

TypePublic
Founded1981
HQWaltham, MA, US
Websiterepligen.com
Employee Ratings3.3

Latest Updates

Employees (est.) (Dec 2020)1,128(+49%)
Job Openings127
Revenue (FY, 2020)$366.3 M(+36%)
Share Price (Jul 2021)$203.6
Cybersecurity ratingCMore

Key People/Management at Repligen

Tony J. Hunt

Tony J. Hunt

President, Chief Executive Officer
Jon K. Snodgres

Jon K. Snodgres

Chief Financial Officer
Ralf Kuriyel

Ralf Kuriyel

Senior Vice President, Research and Development
Jim Bylund

Jim Bylund

Senior Vice President, Operations and Information Technology
Gautam Choudhary

Gautam Choudhary

Vice President, Systems and Automation
Steve Curran

Steve Curran

Vice President, Global Operations
Show more

Repligen Office Locations

Repligen has offices in Waltham, Bridgewater Township, Compton, Irving and in 10 other locations
Waltham, MA, US (HQ)
41 Seyon St #100
Bridgewater Township, NJ, US
685 US-202
Compton, CA, US
18617 S Broadwick St
Irving, TX, US
3400 Royalty Row
Marlborough, MA, US
111 Locke Dr, Marlborough
New York, NY, US
Fairchild Square, Clifton Park
Show all (14)

Repligen Financials and Metrics

Repligen Revenue

Embed Graph
View revenue for all periods
Repligen's revenue was reported to be $366.26 m in FY, 2020 which is a 35.5% increase from the previous period.
USD

Revenue (Q1, 2021)

142.8m

Gross profit (Q1, 2021)

83.1m

Gross profit margin (Q1, 2021), %

58.2%

Net income (Q1, 2021)

29.5m

EBIT (Q1, 2021)

36.4m

Market capitalization (21-Jul-2021)

11.2b

Closing stock price (21-Jul-2021)

203.6

Cash (31-Mar-2021)

711.3m

EV

11.0b
Repligen's current market capitalization is $11.2 b.
Annual
USDFY, 2018FY, 2019FY, 2020

Revenue

194.0m270.2m366.3m

Revenue growth, %

37%39%36%

Cost of goods sold

86.5m119.1m156.6m

Gross profit

107.5m151.1m209.6m
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

44.8m47.7m49.5m60.6m70.7m69.4m76.1m87.5m94.1m142.8m

Cost of goods sold

19.7m21.1m22.2m26.8m30.7m31.4m32.0m36.9m39.6m59.7m

Gross profit

25.2m26.6m27.3m33.8m40.0m38.0m44.1m50.6m54.4m83.1m

Gross profit Margin, %

56%56%55%56%57%55%58%58%58%58%
Annual
USDFY, 2018FY, 2019FY, 2020

Cash

193.8m528.4m717.3m

Accounts Receivable

33.0m43.1m71.3m

Prepaid Expenses

3.9m5.9m18.7m

Inventories

42.3m54.8m95.0m
Quarterly
Annual
USDFY, 2018FY, 2019FY, 2020

Net Income

16.6m21.4m59.9m

Depreciation and Amortization

15.8m20.9m27.1m

Inventories

(4.0m)(9.3m)(29.3m)

Accounts Payable

2.3m662.0k2.5m
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income

3.4m6.2m11.0m8.1m16.1m17.8m9.8m25.7m40.2m29.5m

Depreciation and Amortization

4.0m7.9m11.8m4.2m9.1m14.8m6.4m12.9m19.6m8.4m

Inventories

(1.2m)(3.1m)(4.8m)(1.5m)(4.1m)(4.9m)(7.2m)(15.0m)(22.8m)(17.0m)

Accounts Payable

(1.5m)(701.0k)3.4m(570.0k)495.0k(780.0k)(709.0k)2.9m3.3m3.7m
USDQ1, 2018

Revenue/Employee

94.2k

Debt/Equity

0.2 x

Debt/Assets

0.1 x

Financial Leverage

1.2 x
Show all financial metrics

Repligen Operating Metrics

FY, 2017FY, 2018FY, 2019FY, 2020

Patent Applications

85106186

Patents Issued

445278

Product Lines

344

Trademarks (Foreign)

34
Show all operating metrics

Repligen Acquisitions / Subsidiaries

Company NameDateDeal Size
ARTeSYN Biosolutions Holdings Ireland LimiteOctober 27, 2020
Non-Metallic Solutions, IncOctober 15, 2020
Engineered Molding Technology LLCJune 26, 2020
C Technologies, Inc.May 31, 2019
Repligen Europe B.V.
Repligen GmbH
Repligen India Private Limited
Repligen Japan LLC
Repligen Korea Co. Ltd.
Repligen (Shanghai) Biotechnology Co. Ltd.
Show more

Repligen Revenue Breakdown

Embed Graph

Repligen revenue breakdown by business segment: 100.0% from Product Revenue and 0.0% from Other

Human Capital Metrics

Embed Graph
Show all human capital metrics

Repligen Cybersecurity Score

Cybersecurity ratingPremium dataset

C

75/100

SecurityScorecard logo

Repligen Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Repligen Online and Social Media Presence

Embed Graph

Repligen News and Updates

Repligen to Report Second Quarter 2021 Financial Results

Webcast and Conference Call to Be Held Tuesday, July 27, 2021 at 8:30 a.m. EDT Webcast and Conference Call to Be Held Tuesday, July 27, 2021 at 8:30 a.m. EDT

Repligen To Buy Polymem For An Undisclosed Sum

Repligen Corporation has agreed to acquire France-based Polymem S.A., a provider of hollow fiber membranes and modules.

Repligen Corporation Announces Agreement to Acquire Polymem S.A.

WALTHAM, Mass., June 22, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has entered into an agreement to acquire Toulouse, France based Polymem S.A. (“Polymem”), a leading industrial exper…

Repligen Corporation to Present at Upcoming Investor Conferences

WALTHAM, Mass., May 25, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtually at two upcoming investor conferences.

Repligen Reports First Quarter 2021 Financial Results and Updates Full Year 2021 Financial Guidance

WALTHAM, Mass., May 04, 2021 (GLOBE NEWSWIRE) --  Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its first quarter ended March 31, 2021. Provided in this press release are financial highlights for the…

Repligen to Report First Quarter 2021 Financial Results

Webcast and Conference Call to Be Held Tuesday, May 4, 2021 at 8:30 a.m. EDT Webcast and Conference Call to Be Held Tuesday, May 4, 2021 at 8:30 a.m. EDT
Show more

Repligen Frequently Asked Questions

  • When was Repligen founded?

    Repligen was founded in 1981.

  • Who are Repligen key executives?

    Repligen's key executives are Tony J. Hunt, Jon K. Snodgres and Ralf Kuriyel.

  • How many employees does Repligen have?

    Repligen has 1,128 employees.

  • What is Repligen revenue?

    Latest Repligen annual revenue is $366.3 m.

  • What is Repligen revenue per employee?

    Latest Repligen revenue per employee is $324.7 k.

  • Who are Repligen competitors?

    Competitors of Repligen include Purdue Pharma, United Therapeutics and Luminex.

  • Where is Repligen headquarters?

    Repligen headquarters is located at 41 Seyon St #100, Waltham.

  • Where are Repligen offices?

    Repligen has offices in Waltham, Bridgewater Township, Compton, Irving and in 10 other locations.

  • How many offices does Repligen have?

    Repligen has 14 offices.